Endocrine side effects of immune checkpoint inhibitors
- Diagnostic approach
Cancer immunotherapy can turn the immune system on the thyroid, pituitary, pancreas or adrenals. The damage lasts, but replacing hormones lets treatment go on.
See it in 3D: Pituitary gland · Thyroid gland · Pancreas · Left adrenal gland
What it is
Immune checkpoint inhibitors (anti-CTLA-4 such as ipilimumab, anti-PD-1 such as nivolumab and pembrolizumab, and anti-PD-L1) release the brakes on T cells so they attack tumours, and sometimes the patient's own glands. Endocrine immune-related adverse events are among the most frequent. Thyroiditis (mainly with PD-1/PD-L1 blockers) is the commonest; hypophysitis is typical of CTLA-4 blockers and combination therapy; insulin-deficient diabetes, primary adrenal insufficiency and hypoparathyroidism are rare but dangerous. Unlike most immune side effects, endocrine damage is usually permanent and is managed with hormone replacement rather than high-dose glucocorticoids, so immunotherapy can usually continue.
What to know
- Thyroid disease is the most common endocrine adverse event, mostly with PD-1/PD-L1 blockers: painless destructive thyroiditis with a short thyrotoxic phase, then hypothyroidism that is often permanent.
- The thyrotoxic phase is destructive, not overproduction: it is treated with a beta-blocker if symptomatic, never with antithyroid drugs; Graves disease is rare.
- Hypophysitis is typical of CTLA-4 blockade and combination therapy, usually in the first months; it presents with headache and fatigue, and ACTH deficiency (central adrenal insufficiency) is the most important deficit.
- ACTH deficiency after checkpoint inhibitors is almost always permanent; TSH and gonadotropin deficits may recover; diabetes insipidus is rare, unlike in other forms of hypophysitis.
- Hypophysitis from PD-1 blockers often causes isolated ACTH deficiency with a normal-looking pituitary on MRI.
- Checkpoint-inhibitor diabetes is rare but sudden: insulin deficiency, often presenting as diabetic ketoacidosis, very low C-peptide, sometimes with GAD antibodies, and an HbA1c that may be only mildly raised because the onset is so fast; it is permanent.
- Primary adrenal insufficiency (adrenalitis) is rare: high ACTH, low cortisol and mineralocorticoid deficiency with hyponatraemia and hyperkalaemia.
- Hypoparathyroidism is very rare and causes severe hypocalcaemia with low PTH.
- High-dose glucocorticoids do not restore gland function; they are used for hypophysitis only with severe mass effect such as visual loss or intractable headache.
- Immunotherapy is usually continued once replacement is in place; it is held only during an acute crisis until the patient is stable.
Step-by-step approach
- Before the first cycle: TSH, free T4, glucose, electrolytes and a morning cortisol, as a baseline.
- Before each cycle: TSH with free T4 and glucose; teach the patient the warning symptoms.
- Low TSH with high free T4 → thyroiditis: beta-blocker for symptoms, repeat in a few weeks, expect hypothyroidism.
- Low or normal TSH with low free T4 → central hypothyroidism: suspect hypophysitis and check cortisol and ACTH at once.
- Low cortisol with low or normal ACTH → hypophysitis; with high ACTH → primary adrenal failure; start hydrocortisone.
- Replace glucocorticoid before thyroxine: thyroxine first speeds cortisol use and can trigger adrenal crisis.
- High glucose, especially with ketones → treat as new insulin-deficient diabetes or DKA; measure C-peptide.
- Unwell, hypotensive, vomiting or confused → treat as adrenal crisis, DKA or severe hypocalcaemia without waiting for results.
- Once stable on replacement, continue immunotherapy; give a steroid card and sick-day rules.
Endocrine adverse events of checkpoint inhibitors: pattern, permanence and treatment
| Disorder | Typical drug class | Laboratory pattern | Permanent? | Treatment |
|---|---|---|---|---|
| Thyroiditis, thyrotoxic phase | PD-1/PD-L1 | Low TSH, high free T4, low uptake | No, transient | Beta-blocker if symptoms; no antithyroid drugs |
| Hypothyroidism | PD-1/PD-L1, after thyroiditis | High TSH, low free T4 | Usually yes | Levothyroxine |
| Hypophysitis | CTLA-4 or combination | Low cortisol with low ACTH; often low TSH, LH, FSH | ACTH deficit yes; others may recover | Hydrocortisone first, then other hormones as needed |
| Insulin-deficient diabetes | PD-1/PD-L1 | High glucose, ketones, very low C-peptide | Yes | Insulin; treat DKA |
| Primary adrenal insufficiency | PD-1/PD-L1 or combination | Low cortisol, high ACTH, high renin | Yes | Hydrocortisone and fludrocortisone |
| Hypoparathyroidism | Any, very rare | Low calcium, low PTH | Usually yes | Calcium and active vitamin D |
Keys to the differential
- Fatigue, nausea and low sodium on immunotherapy are easily blamed on the cancer; a morning cortisol and ACTH make the diagnosis of hypophysitis or adrenal failure.
- Headache in the first months of ipilimumab-containing therapy suggests hypophysitis; a pituitary MRI usually shows enlargement, whereas PD-1-related hypophysitis often does not.
- A low TSH can mean two opposite things on checkpoint inhibitors: thyroiditis if free T4 is high, central hypothyroidism if free T4 is low.
- Patients already taking glucocorticoids for another immune side effect have suppressed cortisol tests; their adrenal axis is assessed after the steroids are tapered.
Next step / Initial management
- Check TSH, free T4 and glucose before every cycle, and morning cortisol with ACTH whenever there is fatigue, hypotension, hyponatraemia or headache.
- Start hydrocortisone at once for adrenal insufficiency, before levothyroxine; give stress-dose treatment and admit if there is hypotension or vomiting.
- Treat new hyperglycaemia with ketones as DKA and start insulin; measure C-peptide and diabetes antibodies to confirm insulin deficiency.
- Continue immunotherapy in most patients once hormone replacement is established, with the oncology team; replacement is usually lifelong.
- Refer to endocrinology every patient with hypophysitis, adrenal insufficiency, new diabetes or hypoparathyroidism, and thyroiditis that is severe or not following the usual course.
Common traps
- Checkpoint thyroiditis needs an antithyroid drug: the thyrotoxic phase is destructive release of stored hormone, so antithyroid drugs do nothing and a beta-blocker is enough.
- High-dose glucocorticoids will rescue the gland: endocrine damage is usually permanent and steroids do not restore function, so replacement is the treatment.
- A low TSH always means too much thyroid hormone: with hypophysitis TSH is low or normal while free T4 is low, which is central hypothyroidism.
- Levothyroxine can be started straight away for low free T4: if ACTH is also deficient, thyroxine first can precipitate adrenal crisis, so cortisol is replaced first.
- Endocrine side effects mean immunotherapy must stop: once hormones are replaced most patients can continue, and stopping would sacrifice cancer control for a manageable deficit.
Test yourself
Think of the answer, then tap the question to see it.
Six weeks into pembrolizumab a man has palpitations, a suppressed TSH and a high free T4, with low radioiodine uptake. What is it and how is it treated?
Painless destructive thyroiditis: a beta-blocker for symptoms, no antithyroid drugs, and repeat tests in a few weeks because hypothyroidism usually follows.
A woman on ipilimumab plus nivolumab has headache, fatigue and sodium of 128 mmol/L; TSH is low-normal and free T4 low. What do you check and give first?
Morning cortisol and ACTH for hypophysitis, and hydrocortisone first, before levothyroxine, because ACTH deficiency is the dangerous deficit.
A patient on a PD-1 inhibitor presents with vomiting, glucose of 480 mg/dL, ketones and an HbA1c of only 7.2%. What is the diagnosis?
Checkpoint-inhibitor insulin-deficient diabetes presenting as DKA; the rapid onset explains the modest HbA1c, C-peptide is very low and insulin is needed for life.
Once a patient with checkpoint-induced hypothyroidism is stable on levothyroxine, should immunotherapy be stopped?
Usually not: endocrine adverse events are managed with replacement, and immunotherapy continues with the oncology team.
Elsewhere in DurgiPedia
- Cancer immunotherapy: checkpoint inhibitors, CAR-T and vaccines
- Antibodies, bispecifics and CAR-T cells: how they work and their emergencies (CRS, ICANS)
- Other thyroiditis: de Quervain, painless, Riedel
- Adrenocortical insufficiency
Connections
See it in 3D4
The structures of Durgical's 3D anatomy where it is found.
Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.
Sources: Endocrine-Related Adverse Events From Immune Checkpoint Inhibitors (StatPearls (NCBI Bookshelf), 2026); Lymphocytic Hypophysitis (StatPearls (NCBI Bookshelf), 2025); Adrenal Insufficiency (StatPearls (NCBI Bookshelf), 2023).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
